Myolaxin/Myolaxin-D

Myolaxin/Myolaxin-D

Manufacturer:

Geno

Distributor:

Nebula

Marketer:

Mascots
Concise Prescribing Info
Contents
Per Myolaxin Capsaicin 0.075% w/w, methyl salicylate 20% w/w, menthol 10% w/w, camphor 5% w/w, eucalyptus oil 5% w/w. Per Myolaxin-D Capsaicin 0.075% w/w, methyl salicylate 20% w/w, menthol 10% w/w, camphor 5% w/w, eucalyptus oil 5% w/w, diclofenac diethylamine 1.16% w/w (equiv to diclofenac Na 1% w/w)
Indications/Uses
Temporary relief of minor aches & pains of muscles & joints due to muscle strains, sprains & bruises or over-exertion. Adjunct in minor stiffness or soreness associated w/ arthritis, rheumatism, lumbago, fibrositis, sciatica & stiff neck.
Dosage/Direction for Use
Special Precautions
Avoid contact w/ eyes. Do not apply to broken skin & excessively raw areas. Exercise care w/ sensitive skin. Avoid local application in childn suffering from influenza & chicken pox. Pregnancy.
Adverse Reactions
Drug Interactions
Capsaicin: May increase the risk of cough w/ ACE inhibitors, risk of bleeding w/ concurrent use of antiplatelet agents; avoid concomitant use of barbiturates as acute use of capsaicin is associated w/ inhibitor of cytochrome P450 enzymes & chronic use w/ increased levels of the enzymes. Increased absorption to theophylline may occur. Monitor theophylline levels & signs & symptoms of theophylline toxicity. Diclofenac Na: Decrease antihypertensive & natriuretic effect of ACE inhibitors; increased BP & interference w/ BP control w/ β-blockers. Co-administration of β-glucan resulted in lethal GI damage in mice. May increase risk of GI hemorrhage w/ Ca channel blockers. Increased spinal hematomas in combination w/ danaparoid; may predispose patient to gastropathy, increased risk of bleeding & nephropathy w/ feverfew; additive GI distress may occur w/ gossypol; caution w/ concomitant use of ibandronate due to risk of GI irritation; risk for CNS stimulation & convulsive seizures w/ levofloxacin & ofloxacin. Increased methotrexate levels & toxicity. Reduction of partial clearance of quinidine by N-oxidation by 33%. Increased risk of bleeding w/ SSRIs. Hypoglycemia may occur w/ sulfonylureas. May be associated w/ anemia or oliguria in liver transplant patients receiving tacrolimus. Exercise caution w/ oral anticoagulants.
ATC Classification
M02AB - Capsaicin and similar agents ; Used in the topical treatment of joint and muscular pains.
M02A - TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN ; Used in the topical treatment of joint and muscular pains.
Presentation/Packing
Form
Myolaxin-D topical gel
Packing/Price
15 g x 1's
Form
Myolaxin topical gel
Packing/Price
15 g x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in